Peak Bio, Inc.
Peak Bio, Inc.
Share · US70470P1084 · PKBO (XNAS)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 150,00 % -99,77 %

Company Profile for Peak Bio, Inc. Share

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Company Data

Name Peak Bio, Inc.
Company Peak Bio, Inc.
Symbol PKBO
Website https://peak-bio.com
Primary Exchange XNAS NASDAQ
ISIN US70470P1084
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Hoyoung Huh M.D., Ph.D.
Country United States of America
Currency USD
Employees 0,0 T
Address 3350 W Bayshore Rd., 94303 Palo Alto
IPO Date 2021-03-15

ID Changes

Date From To
02.11.2022 IGNY PKBO

Ticker Symbols

Name Symbol
NASDAQ PKBO

More Shares

Investors who Peak Bio, Inc. hold also have the following shares in their portfolio:
LBBW GM-FLOATER 17/21
LBBW GM-FLOATER 17/21 Bond
Vanguard New Jersey Long-Term Tax-Exempt Fund Investor Shares
Vanguard New Jersey Long-Term Tax-Exempt Fund Investor Shares ETF
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025